Bone and Joint Reconstruction Research Center, Department of Orthopedics, School of Medicine, Iran University of Medical Sciences, Tehran, Iran.
Taleghani Hospital, Research Development Unit, Department of Orthopedic Surgery, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
J Arthroplasty. 2022 Nov;37(11):2233-2238. doi: 10.1016/j.arth.2022.05.042. Epub 2022 May 29.
Extensor mechanism reconstruction after the proximal tibial resection and implantation of a megaprosthesis is challenging. In this study, we evaluated the effectiveness of the Trevira tube and medial gastrocnemius flap in restoring extensor mechanism following the resection of proximal tibial tumor and implantation of megaprosthesis.
Forty patients who underwent endoprosthetic implantation following the resection of proximal tibial tumor and patellar tendon reconstruction with the Trevira tube and medial gastrocnemius flap were included. The outcome measures were knee range of motion, extensor mechanism function, patellar position, and limb function subjectively evaluated through Toronto Extremity Salvage Score and objectively through Musculoskeletal Tumor Society score. The mean follow-up of the patients was 6.1 years.
The patellar position was normal in 28 (70%) patients, patella baja in 3 (7.5%) patients, and patella alta in 9 (22.5%) patients. The mean active knee range of motion was 98.9 ± 17° (range: 85°-125°). Extension lag was present in 7 (17.5%) patients (range: 5°-20°). The mean Toronto Extremity Salvage Score of patients was 92.1 ± 6.9% (range: 85-100). The mean Musculoskeletal Tumor Society score of the patients was 87.7 ± 13 (range: 73.3-100). Postoperative complications included aseptic wound dehiscence (2 patients), aseptic loosening of the tibial component (1 patient), periprosthetic fracture in the femur (2 patients), and wound infection (1 patient).
Trevira tube combined with gastrocnemius flap augmentation is a suitable procedure for restoring extensor mechanism after proximal tibial resection and megaprosthesis implantation.
胫骨近端切除和植入大型假体后,伸肌机制的重建具有挑战性。在这项研究中,我们评估了 Trevira 管和内侧腓肠肌瓣在切除胫骨近端肿瘤和植入大型假体后重建伸肌机制的效果。
纳入 40 例接受胫骨近端肿瘤切除和 Trevira 管及内侧腓肠肌瓣重建髌腱后行假体植入的患者。评估的结果指标包括膝关节活动度、伸肌机制功能、髌骨位置和通过多伦多肢体挽救评分进行的肢体功能的主观评估,以及通过肌肉骨骼肿瘤学会评分进行的客观评估。患者的平均随访时间为 6.1 年。
28 例(70%)患者髌骨位置正常,3 例(7.5%)患者髌骨低位,9 例(22.5%)患者髌骨高位。平均主动膝关节活动度为 98.9±17°(范围:85°-125°)。7 例(17.5%)患者存在伸膝迟滞(范围:5°-20°)。患者的多伦多肢体挽救评分平均为 92.1±6.9%(范围:85-100)。患者的肌肉骨骼肿瘤学会评分平均为 87.7±13(范围:73.3-100)。术后并发症包括无菌性伤口裂开(2 例)、胫骨组件无菌性松动(1 例)、股骨假体周围骨折(2 例)和伤口感染(1 例)。
Trevira 管联合腓肠肌瓣增强是胫骨近端切除和大型假体植入后重建伸肌机制的一种合适方法。